Latest Breaking News On - Protocol planned interim report data - Page 1 : vimarsana.com

Investegate announcements from AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer

United statesThomask equelsRobert edwardsUniversity of pittsburgh medical centerGynecology reproductive sciencesGynecologic oncology research at magee womens hospitalExchange commissionImmunotech incDepartment of obstetricsTech announces positive top lineProtocol planned interim report dataAmpligen combinedRecurrent ovarianImmune checkpoint blockadePittsburgh medical centerObjective response rate